1 citations · 1 across the 1 of their papers we have counts for
4 papers
The use of registry data to extrapolate overall survival results from randomised controlled trials
Reynaldo Martina, Keith Abrams, Sylwia Bujkiewicz +5
Background: Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in randomised controlled trials (RCTs). However, for regulatory an…
A Bayesian hierarchical meta-analytic method for modelling surrogate relationships that vary across treatment classes using aggregate data
Tasos Papanikos, John Thompson, Keith Abrams +4
Surrogate endpoints play an important role in drug development when they can be used to measure treatment effect early compared to the final clinical outcome and to predict clinica…
Impact of model misspecification in shared frailty survival models
Alessandro Gasparini, Mark S. Clements, Keith R. Abrams +1
Survival models incorporating random effects to account for unmeasured heterogeneity are being increasingly used in biostatistical and applied research. Specifically, unmeasured co…
Mixed effects models for healthcare longitudinal data with an informative visiting process: a Monte Carlo simulation study
Alessandro Gasparini, Keith R. Abrams, Jessica K. Barrett +4
Electronic health records are being increasingly used in medical research to answer more relevant and detailed clinical questions; however, they pose new and significant methodolog…